Coronary no-reflow and adverse events in patients with acute myocardial infarction after percutaneous coronary intervention with current drug-eluting stents and third-generation P2Y₁₂ inhibitors.

ABSTRACT:

Background

The frequency and prognostic value of coronary no-reflow (CNR) was investigated in studies that have used an outdated reperfusion therapy in terms of stent technology and antithrombotic drugs. We assessed the association of CNR with adverse outcomes in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES) and newer antithrombotic drugs, ticagrelor or prasugrel.

Methods

This study included 3100 patients with AMI who underwent PCI with current DES and third-generation P2Y₁₂ inhibitors. CNR was defined as Thrombolysis in Myocardial Infarction (TIMI) blood flow grade ≤ 2 at the end of PCI. The primary end point was 1-year incidence of net adverse clinical and cerebral events-a comp

SUBMITTER: Ndrepepa G 

PROVIDER: S-EPMC11219448 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature